SCHEMBL6159586

SCHEMBL6159586

CS(=O)(=O)Nc1ccc(Oc2ccc(CN3C[C@H](S)CC3=O)cn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.41
EGLN1 Q9GZT9 11/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
AR P10275 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
PGR P06401 1/20 0.38
CACNA1F O60840 1/20 0.38
CHRM2 P08172 1/20 0.38
ACHE P22303 1/20 0.38
AGTR1 P30556 1/20 0.38
DRD3 P35462 1/20 0.38
CACNA1D Q01668 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38
MMP2 P08253 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158665 0.89 LTA4H (0.46) LTA4HNPC1RAB9AARHPGD
SCHEMBL6162044 0.88 EGLN1 (0.40) LTA4HEGLN1NPC1RAB9AAR
SCHEMBL6160543 0.87 LTA4H (0.38) LTA4HEGLN1NPC1RAB9AAR
SCHEMBL6160535 0.87 LTA4H (0.38) LTA4HEGLN1NPC1RAB9AAR
SCHEMBL6160304 0.84 EGLN1 (0.51) EGLN1HCRTR1HCRTR2
SCHEMBL6159802 0.84 EGLN1 (0.40) LTA4HEGLN1HCRTR1HCRTR2
SCHEMBL6161230 0.84 EGLN1 (0.40) LTA4HEGLN1HCRTR1HCRTR2
SCHEMBL6161240 0.84 EGLN1 (0.40) LTA4HEGLN1HCRTR1HCRTR2
SCHEMBL6162075 0.82 EGLN1 (0.51) EGLN1HCRTR1HCRTR2MMP2MMP3
Hydrochloric Acid SCHEMBL6159472 0.81 EGLN1 (0.50) EGLN1HCRTR1HCRTR2MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050165064-A1 Novel thiol derivative, process for producing the same and use thereof TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. 2005-07-28 US disclosed
EP-1500658-A1 NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165064-A1 Novel thiol derivative, process for producing the same and use thereof TST, QSOX1, MMP1 LTA4H 718/4885EGLN1 841/4885NPC1 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.